

---

# S&P TEST

SWOT & PESTLE.com

---

## GRIFOLS S.A. SWOT & PESTLE ANALYSIS

© Barakaat Consulting - An Ezzy IT Consulting Business

This is a licensed product and is not to be photocopied or distributed. All rights reserved. Unauthorized reproduction is strictly prohibited. Research is based on best available materials and resources. To purchase reprints of this document, please email [support@swotandpestle.com](mailto:support@swotandpestle.com).

**Company Name :** Grifols S.A.

**Company Sector :** Healthcare

**Operating Geography :** Spain, Europe, Global

**About the Company :**

Having its headquarters in Spain, Grifols SA is a multinational specialised pharmaceutical firm that creates, produces, and distributes a wide variety of biological drugs based on proteins extracted from plasma. The laboratory that hematologist and scientist Dr Josep A. Grifols Roig established in Barcelona in 1940 is where Grifols got its start. It divides its operations into the following five categories: bioscience, diagnostic, hospitals, bio supplies, and others. The production of plasma derivatives for therapeutic purposes as well as the marketing and distribution of finished goods are all included in the field of biology. Diagnostics is primarily concerned with the development, manufacture, and marketing of in-vitro diagnostics products for laboratories, including analytical tools, reagents, and software. The hospital supplies physiological saline solution, enteral nutritional fluids, medical devices for interventional therapy, as well as technologies and services for hospitals, clinics, and specialized facilities for the creation of medications. Most of the items offered by Bio Supplies are biological for non-therapeutic use. Others offer manufacturing services to independent businesses. The corporation announced in April 2022 that it had completed the acquisition of Biotest, a strategic and transformative move meant to spur development and innovation.

The unique selling proposition of Grifols is that it has been a pioneer in plasma-derived medicines for more than 110 years, enhancing people's health and well-being. The mission statement of Grifols reads, "Every day all Grifols employees work toward our mission of improving the health and well-being of people around the world. Our plasma-derived medicines and other innovative solutions treat millions of patients with chronic, rare and prevalent, sometimes, life-threatening diseases".

**Revenue :**

4,933 million - FY ending 31st December 2021

5,353 million - FY ending 31st December 2020

## SWOT Analysis :

The SWOT Analysis for Grifols S.A. is given below:

Strengths	Weaknesses
<ul style="list-style-type: none"> <li>1.Outstanding manufacturing ability diversified across geography</li> <li>2.Vertically integrated business model improving overall efficiency</li> <li>3.World class R&amp;D capabilities</li> <li>4.Inhouse engineering to lead Grifols manufacturing projects</li> </ul>	<ul style="list-style-type: none"> <li>1. High dependence on bioscience division for its revenue</li> <li>2.Poor shareholders return compared to biotech industry and Spanish share market</li> <li>3.High debt eroding company profitability</li> <li>4.Downgrading of company ratings by S&amp;P global and Moody's</li> </ul>
Opportunities	Threats
<ul style="list-style-type: none"> <li>1.Strategic partnership to drive growth in China</li> <li>2.Expand plasma center network to increase access to plasma</li> <li>3.Increased demand for plasma therapy due to Covid-19</li> </ul>	<ul style="list-style-type: none"> <li>1.Misconceptions related to plasma therapy</li> <li>2.Decrease in plasma donations threatens company output</li> <li>3.Rising covid-19 cases can affect Grifols operations</li> </ul>

## PESTLE Analysis :

The PESTLE Analysis for Grifols S.A. is given below:

Political	Economical
1.Governments dropping plasma therapy as Covid-19 treatment 2.Strategic Partnership with Egyptian government	1.Rising inflation in the US can erode company's profits 2.Exposure to currency risks due to fluctuation exchange rates
Social	Technological
1.Aging population in US and Europe 2.Rising dementia cases worldwide	1.Development of Plasma therapy as a possible treatment for Alzheimer's 2.Digital innovation adding value to Grifols business model
Legal	Environmental
1.Ban on gays and transgender for blood donation 2.Grifols and CSL team up for lawsuit against US customs and border agency	1.Grifols taken up several initiatives for environmental protection

Please note that our free summary reports contain the SWOT and PESTLE table contents only. The complete report for **Grifols S.A.** SWOT & PESTLE Analysis is a paid report at **27 U.S.D.**



\* By clicking on "Buy Now" you agree to accept our "Terms and Conditions."



# S&P

SWOT & PESTLE.com

SWOT & PESTLE.com is a leading strategy research portal covering detailed Strengths, Weaknesses, Opportunities, Threats (SWOT) and Political, Economic, Social, Technological, Legal and Environmental (PESTLE) analysis of leading industry sectors and organizations across the globe. Our full and comprehensive collection on SWOT and PESTLE has been written by our team of professional analysts consisting of MBA's, CFA's and industry experts. Our analysis has helped businesses, researchers and scholars with valuable insights to make strategic decisions and take their research forward.

We at SWOT & PESTLE.com aim to aid the understanding of the multifaceted business world by presenting a list of diverse companies from across the globe. Business organizations today cannot function in ways that ignore the surroundings that they are set in. SWOT & PESTLE.com makes a keen observation into this aspect and accounts for factors affecting such businesses.

# Copyright Notice

The information provided in the SWOT and PESTLE research reports on [www.swotandpestle.com](http://www.swotandpestle.com) are from publicly available documents and sources which are deemed reliable. Further the reports contain analysis and views from the SWOT & PESTLE.com research and analyst team which consists of qualified experts. While every attempt has been made to ensure completeness, accuracy and reliability of the analysis, Barakaat Consulting and its associate websites cannot be held responsible or legal liable for omissions or errors in our reports or on any of our pages.

(C)2024 Barakaat Consulting. All rights reserved. This report may not be reproduced, copied or redistributed, in whole or in part, in any form or by any means, without the express written consent of Barakaat Consulting. Also, Barakaat Consulting is the sole copyright owner of this report, and any use of this report by any third party is strictly prohibited without a license expressly granted by Barakaat Consulting. Neither all nor any part of the contents of this report, or any opinions expressed herein, can be used in advertising, press releases, or promotional materials without prior written approval from Barakaat Consulting. Any violation of Barakaat Consultings rights in this report will be executed to the fullest extent of the law, including the pursuit of monetary damages and injunctive relief in the event of any breach of the foregoing restrictions.

Client Support:  
**[support@swotandpestle.com](mailto:support@swotandpestle.com)**